Quick Answer
20/20 Biolabs, Inc. reported Total Revenue of $2.05 million for fiscal year 2025.
20/20 Biolabs, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $2.05M +16.7% |
$1.75M | — |
| Net Income | -$3.74M +32.7% |
-$5.55M | — |
| Diluted EPS | -$0.76 +34.5% |
-$1.16 | — |
| Total Assets | $4.14M +15.4% |
$3.58M | — |
| Cash and Equivalents | $1.03M -42.5% |
$1.78M | — |
| Stockholders Equity | -$19.2K -101.3% |
$1.51M -64.9% |
$4.29M |
| R&D Expense | $592.6K -53.0% |
$1.26M | — |
| Operating Income | -$3.33M +41.3% |
-$5.68M | — |
| Gross Profit | $604.5K +67.8% |
$360.3K | — |
| Shares Outstanding | 5.44M +12.8% |
4.82M | — |
- 20/20 Biolabs, Inc. reported Total Revenue of $2.05 million for fiscal year 2025.
- 20/20 Biolabs, Inc. showed an increase of +16.7% in Total Revenue compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Net Income of -$3.74 million for fiscal year 2025.
- 20/20 Biolabs, Inc. showed an increase of +32.7% in Net Income compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Diluted EPS of $0.76 per share (loss) for fiscal year 2025.
- 20/20 Biolabs, Inc. showed an increase of +34.5% in Diluted EPS compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Total Assets of $4.14 million for fiscal year 2025.
- 20/20 Biolabs, Inc. showed an increase of +15.4% in Total Assets compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Cash and Equivalents of $1.03 million for fiscal year 2025.
- 20/20 Biolabs, Inc. showed a decrease of -42.5% in Cash and Equivalents compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Stockholders Equity of -$19.2 thousand for fiscal year 2025.
- 20/20 Biolabs, Inc. showed a decrease of -101.3% in Stockholders Equity compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported R&D Expense of $592.6 thousand for fiscal year 2025.
- 20/20 Biolabs, Inc. showed a decrease of -53.0% in R&D Expense compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Operating Income of -$3.33 million for fiscal year 2025.
- 20/20 Biolabs, Inc. showed an increase of +41.3% in Operating Income compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Gross Profit of $604.5 thousand for fiscal year 2025.
- 20/20 Biolabs, Inc. showed an increase of +67.8% in Gross Profit compared to the prior fiscal year.
- 20/20 Biolabs, Inc. reported Shares Outstanding of 5.44 million shares for fiscal year 2025.
- 20/20 Biolabs, Inc. showed an increase of +12.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: